Erste deutsche Patienten melden sich zu den klinischen Phase-3-Studien von LMTX™ zur Alzheimer-Krankheit an

Jan 09 - 2014 08:46 AM
Klinische Studien beginnen in Deutschland mit einem Tau-Aggregationshemmer (TAI) der zweiten Generation mit dem Ziel, das Fortschreiten von Alzheimer zu stoppen
Read more

First German patients enroll in Phase 3 clinical trials of LMTX™ for Alzheimer’s Disease

Jan 08 - 2014 06:00 AM
Clinical trials get under way in Germany with a second-generation tau aggregation inhibitor (TAI) aimed at halting the progression of Alzheimer’s
Read more

TauRx Expands Alzheimer’s Clinical Trials in the United States

Jan 05 - 2014 06:00 AM
Clinical research centers added to allow more patients to access a tau-based investigational treatment for mild to moderate Alzheimer’s disease
Read more

Chairman of TauRx and Dr Emer MacSweeney of Re:Cognition Health to speak at ADI Middle East Conference in Dubai on 8-9 December

Dec 06 - 2013 04:54 PM
Two innovative UK thought leaders in Alzheimer’s disease will be speaking at the upcoming 2nd Middle East and North Africa Conference of Alzheimer's Disease International this weekend.
Read more

In Croatia, three international leaders in Alzheimer’s discuss ongoing clinical trials and global dementia policy ahead of the G8 Dementia Research Summit in London next week

Dec 06 - 2013 04:26 PM
Professor Claude Wischik, Chairman of TauRx Therapeutics, Marc Wortmann, Executive Director of Alzheimer’s Disease International (ADI), and Prof. Ninoslav Mimica, President of Alzheimer Croatia, provide the latest news about ADI’s global dementia policy and the Croatian launch of a global Alzheimer’s Research Study
Read more